Hard on the heels of Regeneron moving its COVID-19 antibody cocktail into late-stage testing, the US government has agreed a deal to ramp up manufacturing – and claim the first doses to be made.

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Regeneron has said it has begun clinical trials of its antibody cocktail therapy for COVID-19, as pharma companies continue their search for treatments as the pandemic continues to cause havoc ...

Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline ...

Regeneron's gene therapy study shows improved ... 2024 US FDA revokes authorization for four COVID antibody drugs The U.S. Food and Drug Administration has revoked the emergency use authorization ...

Sanofi and Regeneron’s blockbuster biologic Dupixent ... Dupixent, a fully human monoclonal antibody, inhibits the signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways ...